Discovery of Fragment-Based Inhibitors of SARS-CoV-2 PL Pro
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.5c02832 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Qiangqiang Wei und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146, United States. Hauptthemen laut MEDLINE: Antiviral Agents, SARS-CoV-2, Coronavirus Papain-Like Proteases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
High Resolution Image Download MS PowerPoint Slide SARS-CoV-2 papain-like protease (PL Pro ) plays a key role in viral replication and the host immune response and is a promising target for developing new antiviral treatments. We previously reported a fragment-based screen to identify hits that bind to SARS-CoV-2 PL Pro . Here, we describe the discovery of potent PL Pro inhibitors by optimizing one of these hits via extensive medicinal chemistry guided by multiple X-ray structures of cocomplexes. Lead compound 46 is shown to bind to the S3 and S4 pockets with nanomolar affinity (0.4 μM) and exhibits robust cellular activity and resistance to mutation. This novel class of PL Pro inhibitors can potentially be used as a starting point for the development of inhibitors to combat the emergence of drug-resistant viral strains and future coronavirus outbreaks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146, United States.
- Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
- Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.
- Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6600, United States.
- Department of Chemistry, Vanderbilt University, Nashville, Tennessee 37235, United States.
ORCID-Profile: Ashley J Taylor, Mahesh Angadrao Barmade, Kevin B Teuscher, Tyson A Rietz, Kangsa Amporndanai, Stephen W Fesik
Förderung
- NIGMS NIH HHS
- NIH HHS
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Wei, Q., Taylor, A. J., Barmade, M. A., Teuscher, K. B., Chowdhury, S., Apakama, C., Anderson-Daniels, J., Yongqing, Z., Schultz, D. C., Rietz, T. A., South, T. M., Crow, M. M., Zhao, B., Amporndanai, K., Sensintaffar, J. L., Phan, J., Cherry, S., Denison, M., Lee, T., & Fesik, S. W. (2026). Discovery of Fragment-Based Inhibitors of SARS-CoV-2 PL Pro. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02832
Vancouver
Wei Q, Taylor AJ, Barmade MA, Teuscher KB, Chowdhury S, Apakama C, et al. Discovery of Fragment-Based Inhibitors of SARS-CoV-2 PL Pro. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.5c02832
BibTeX
@article{Wei2026,
author = {Wei, Qiangqiang and Taylor, Ashley J and Barmade, Mahesh Angadrao and Teuscher, Kevin B and Chowdhury, Somanath and Apakama, Chideraa and Anderson-Daniels, Jordan and Yongqing, Zhu and Schultz, David C and Rietz, Tyson A and South, Taylor M and Crow, Mackenzie M and Zhao, Bin and Amporndanai, Kangsa and Sensintaffar, John L and Phan, Jason and Cherry, Sara and Denison, Mark and Lee, Taekyu and Fesik, Stephen W},
title = {Discovery of Fragment-Based Inhibitors of SARS-CoV-2 PL Pro},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.5c02832}
}
EUVIMED